论文部分内容阅读
AIM:To evaluate the feasibility and safety of the intraarterialchemotherapy of the liver cancer by an interventionalmethod,catheter-port system.METHODS:Thirty-two catheter-port systems wereimplanted percutaneously via the femoral artery orsubclavian artery.Chemotherapies were performed 0-5 dafter the implantation of the catheter-port systems.Themean interval between two sequent chemotherapies was4wk.The occurrence of side effects of the implantationwas examined clinically.RESULTS:Implantation of the catheter-port was successfulin all patients.Mean patency period was 210 d.One occlusion(3.1%) of the catheter was observed.Displacement of thecatheter was observed in one case (3.1%).One patientrated a hematoma in the chest wall as important.Mildhematoma was reported in 8 cases (25%).In 3 of 32 cases(9.4%),mild pain was reported initially,and dysesthesiawas reported in seven (21.9%).No patient rated overalldiscomfort as mild,severe,or important.CONCLUSION:Percutaneous placement is feasible andsafe for liver regional continuous chemotherapy.Comparedwith surgical placement,the overall complication rate iscomparable or less.
AIM: To evaluate the feasibility and safety of the intraarterial chemotherapy of the liver cancer by an interventional method, catheter-port system. METHODS: Thirty-two catheter-port systems wereimplanted percutaneously via the femoral artery orsubclavian artery. Chemotherapies were performed 0-5 dafter the implantation of the catheter-port systems. memean interval between two sequent chemotherapies was4wk. the occurrence of side effects of the implantationwas examined clinically .RESULTS: Implantation of the catheter-port was successfulin all patients .Mean patency period was 210 d.One occlusion ( 3.1%) of the catheter was observed. Displacement of the Catheter was observed in one case (3.1%). One patientrated a hematoma in the chest wall as important. 9.4%), mild pain was reported initially, and dysesthesiawas reported in seven (21.9%). No patient rated overall disco was as mild, severe, or important. CONCLUSION: Percutaneous placement is feasible andsafe for liver regional continuous chemotherapy .Comparedwith surgical placement, the overall complication rate iscomparable or less.